MedTrace Logo

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

NCT06371157 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 469

Last updated 2025-03-12

No results posted yet for this study

Summary

A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma

Conditions

Interventions

DRUG

AK104

intravenous

DRUG

Lenvatinib

oral

PROCEDURE

TACE

TACE (chemo and embolic agent injection into the hepatic artery)

OTHER

Placebo for AK104

intravenous

OTHER

Placebo for Lenvatinib

oral

Sponsors & Collaborators

Principal Investigators

  • Guoliang Shao, MD · Zhejiang Cancer Hospital

  • Gaojun Teng, MD · Zhongda Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-02
Primary Completion
2025-10-25
Completion
2026-05-23

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06371157 on ClinicalTrials.gov